Generic Name:
semaglutide
Project Status:
Complete
Therapeutic Area:
diabetes mellitus, type 2
Manufacturer:
Novo Nordisk Canada Inc.
Brand Name:
Rybelsus
Project Line:
Reimbursement Review
Project Number:
SR0637-000
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with type 2 diabetes to improve glycemic control: in combination with metformin, and in combination with metformin and sulfonylurea
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in combination with other medicinal products for the treatment of diabetes
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.